How do manufacturers appoint a rapporteur and assessment team responsible for assessing their marketing approval applications in the European Union for advanced therapy medicinal products, including ones that are ATMP/device combinations?
This question is covered in a paper that was adopted recently by the European Medicine Agency’s Committee for Human Medicinal Products and that has just been published on the EMA website1...
Please login to read the full article.
